海角破解版

EasySep? Human CD34 Positive Selection Kit II

Immunomagnetic positive selection of human CD34+ cells

EasySep? Human CD34 Positive Selection Kit II

Immunomagnetic positive selection of human CD34+ cells

Catalog #
(Select a product)
Immunomagnetic positive selection of human CD34+ cells
Request Pricing Request Pricing

Product Advantages


  • Fast and easy-to-use

  • Up to 99% purity

  • No columns required

What's Included

  • EasySep? Human CD34 Positive Selection Kit II (Catalog #17856)
    • EasySep? Human CD34 Positive Selection Cocktail, 1 x 1 mL
    • EasySep? Dextran RapidSpheres? 50100, 1 x 1 mL
  • EasySep? Human CD34 Positive Selection Kit II (Catalog #100-1569)
    • EasySep? Human CD34 Positive Selection Cocktail, 1 x 10 mL
    • EasySep? Dextran RapidSpheres? 50103, 1 x 1 mL
  • RoboSep? Human CD34 Positive Selection Kit II with Filter Tips (Catalog #17856RF)
    • EasySep? Human CD34 Positive Selection Cocktail, 1 x 1 mL
    • EasySep? Dextran RapidSpheres? 50100, 1 x 1 mL
    • RoboSep? Buffer (Catalog #20104)
    • RoboSep? Filter Tips (Catalog #20125)

Overview

Isolate highly purified human CD34+ cells from fresh or previously frozen mobilized human peripheral blood or bone marrow mononuclear cells (MNCs), previously frozen cord blood MNCs, or human embryonic stem (ES) and induced pluripotent stem (iPS) cell cultures by immunomagnetic positive selection, with the EasySep? Human CD34 Positive Selection Kit II. Widely used in published research for more than 20 years, EasySep? combines the specificity of monoclonal antibodies with the simplicity of a column-free magnetic system.

In this EasySep? positive selection procedure, desired cells are labeled with antibody complexes recognizing CD34 and magnetic particles. The cocktail in this kit also contains an antibody to human Fc receptor to prevent non-specific binding. Labeled cells are separated using an EasySep? magnet and by simply pouring off the unwanted cells. The cells of interest remain in the tube. Following magnetic cell isolation, the desired human CD34+ cells are ready for downstream applications such as flow cytometry, culture, or DNA/RNA extraction. The CD34 antigen is expressed on hematopoietic stem and progenitor cells.

This product replaces the EasySep? Human CD34 Positive Selection Kit (Catalog #18056) for even faster cell isolations.

For large-scale isolation of human CD34+ cells from mobilized leukopaks, see the large-format (1x10^10 cells) kit (Catalog #100-1569).

Learn more about how immunomagnetic EasySep? technology works or how to fully automate immunomagnetic cell isolation with RoboSep?. Explore additional products optimized for your workflow, including culture media, supplements, antibodies, and more.

Magnet Compatibility
? EasySep? Magnet (Catalog #18000)
? “The Big Easy” EasySep? Magnet (Catalog #18001)
? RoboSep?-S (Catalog #21000)
? Easy 250 EasySep? Magnet (Catalog #100-0821)
Subtype
Cell Isolation Kits
Cell Type
Hematopoietic Stem and Progenitor Cells, Pluripotent Stem Cells
Species
Human
Sample Source
Bone Marrow, Cord Blood, Other, PBMC, Pluripotent Stem Cells, Whole Blood, Mobilized Leukopaks
Selection Method
Positive
Application
Cell Isolation
Brand
EasySep, RoboSep
Area of Interest
Chimerism, Immunology, Stem Cell Biology

Data Figures

Typical EasySep? Human CD34 Positive Selection Kit II Isolation Profile

Figure 1. Typical EasySep? Human CD34 Positive Selection Kit II Isolation Profile

Starting with cord blood, mobilized peripheral blood or bone marrow MNCs, or ES and iPS cell cultures, the CD34+ cell content of the isolated fraction is typically 93.5 ± 1.1% (mean ± SD), using the purple EasySep? Magnet. In the above example using frozen cord blood, the purities of the start and final isolated fractions are 2.2% and 94.7%, respectively.

FACS Data for Anti-Human CD34 Antibody, Clone 581, Alexa Fluor? 488-Conjugated

Figure 2. FACS Data for Anti-Human CD34 Antibody, Clone 581, Alexa Fluor? 488-Conjugated

(A) Flow cytometry analysis of human peripheral blood mononuclear cells (PBMCs) labeled with Anti-Human CD34 Antibody, Clone 581, Alexa Fluor? 488 (Catalog #60013AD) and Anti-Human CD45 Antibody, Clone HI30, APC (Catalog #60018AZ). (B) Flow cytometry analysis of PBMCs labeled with Mouse IgG1, kappa Isotype Control Antibody, Clone MOPC-21, Alexa Fluor? 488 (Catalog #60070AD), and Anti-Human CD45 Antibody, Clone HI30, APC. (C) Flow cytometry analysis of human PBMCs processed with the EasySep? Human CD34 Positive Selection Kit (Catalog #17856) and labeled with Anti-Human CD34 Antibody, Clone 581, APC. Histograms show labeling of PBMCs (Start) and isolated cells (Isolated). Labeling of start cells with Mouse IgG1, kappa Isotype Control Antibody, Clone MOPC-21, Alexa Fluor? 488 is shown (solid line histogram).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Name
Catalog #
100-1569
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17856RF, 17856
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17856RF, 17856
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17856RF, 17856
Lot #
All
Language
English
Document Type
Product Name
Catalog #
17856RF
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (45)

Heterogeneous Activated B Cell Compartments Arising Early and Transiently After SARS‐CoV‐2 Vaccination L. F. Blanco et al. European Journal of Immunology 2026 Mar

Abstract

In humans, the stages and dynamics of B cell development after antigen encounter remain unclear. Identifying early B cell differentiation stages could reveal biomarkers for humoral immunity and potential targets to prevent unwanted antibody responses. We characterized antigen‐specific B cell responses longitudinally after SARS‐CoV‐2 mRNA vaccination using multiparameter spectral flow cytometry. Spike‐specific IgG+ CD27+ CD71+ activated B cells (ActBCs), presumed to be germinal center‐derived and IgG+ DN2 extrafollicular B cells, dominated the early antigen‐specific B cell response, while memory B cells were the main population 6 months after vaccination. Within the IgG+ ActBC compartment, we delineated six novel clusters with specific contraction dynamics. Following the second vaccination, certain ActBC clusters displayed sustained expansion over time, being phenotypically similar to memory B cells, while others strongly expanded and subsequently contracted. Several of the rapidly contracting ActBC clusters expressed CD11c, a defining marker for atypical B cells, suggesting a possible extrafollicular origin of these clusters. The transient presence of heterogeneous ActBC clusters was also observed for total B cells when gated in an antigen‐independent manner. Characterization of novel ActBC clusters early after antigen encounter helps delineate and dissect the complexity of B cell differentiation, which is vital for understanding unwanted B cell responses. Characterization of the early antigen‐specific B cell response post‐SARS‐CoV‐2 vaccination reveals novel activated B cell clusters, showing different phenotypes and contraction dynamics. Some short‐lived activated B cells expressed both CD71 and the extrafollicular marker CD11c. These results advance our understanding of B‐cell differentiation regulation and biomarker potential.
Hyaluronic acid-CD44 signaling defines therapeutic resistance and immunosuppressive microenvironment in peritoneal metastasis of gastric cancer J. Zhao et al. Journal for Immunotherapy of Cancer 2026 Mar

Abstract

AbstractBackgroundPeritoneal metastasis (PM) is one of the most challenging clinical problems in gastric cancer (GC), largely due to its high recurrence rate and poor response to current therapies. Increasing evidence indicates that remodeling of the extracellular matrix (ECM) plays an important role in therapeutic failure. However, how specific stromal–immune interactions contribute to PM heterogeneity and immunotherapy resistance remains unclear. In this study, we investigated how ECM composition—particularly the accumulation of hyaluronic acid (HA)—influences the immune microenvironment and therapeutic responses in GC-associated PM.MethodsWe combined histopathological assessment, analyses of patient-derived specimens, single-cell transcriptomic profiling, and murine models of PM to delineate ECM remodeling patterns and immune cell dynamics in therapy-sensitive and therapy-resistant lesions. In addition, functional assays and pharmacological approaches were used to examine HA–CD44 signaling and its impact on CD4+ T cell differentiation and responsiveness to immune checkpoint blockade.ResultsTherapy-sensitive PM lesions were characterized by enrichment of elastic fibers, whereas therapy-resistant lesions showed collagen accumulation. Notably, HA deposition emerged as a key feature distinguishing these ECM states and was closely associated with differential therapeutic outcomes. Elevated HA levels activated CD44-dependent signaling in CD4+ T cells, driving regulatory T cell (Treg) differentiation through a CD44–IQGAP1–RAC1–SMAD3 signaling pathway and thereby establishing an immunosuppressive microenvironment. Importantly, pharmacological inhibition of CD44 reduced Treg expansion and markedly enhanced the antitumor efficacy of anti-PD-1 therapy in murine PM models.ConclusionsOur findings identify HA–CD44 signaling as a critical link between ECM remodeling and immune evasion in GC PM. Targeting ECM-driven immunosuppressive mechanisms may represent a promising strategy to overcome therapeutic resistance and improve the efficacy of immunotherapy in this aggressive disease.
Platelet Releasate Reprograms Synovial Macrophages In Vitro: A New Approach in the Treatment of Hemophilic Synovitis P. Oneto et al. International Journal of Molecular Sciences 2025 Oct

Abstract

Chronic hemophilic synovitis (CHS), driven by hemosiderin-laden macrophages from recurrent hemarthrosis, is a major cause of joint damage in hemophilia. Platelet-rich plasma (PRP) is a promising regenerative therapy for joint diseases. This study investigated PRP’s ability to modulate macrophage polarization from a pro-inflammatory (M1) to a pro-resolving, tissue-repairing (M2) phenotype in CHS. We analyzed synovial fluid (SF) from CHS patients (N = 22), both pre- and post-PRP treatment. Ex vivo analysis revealed a predominant M1 profile with an increased proportion of CD11+CD14+CD64hi compared with CD206+ or CD163+ M2 macrophages in CHS SF. In vitro experiments showed that CHS SF skewed monocyte-derived macrophages toward an M1 inflammatory program, evaluated by flow cytometry, qPCR, and ELISA. However, adding PRP significantly modulated the pro-inflammatory macrophage program, promoting an M2 tissue repair profile. Furthermore, a random forest machine learning algorithm, applied to public scRNAseq data, confirmed PRP’s macrophage reprogramming effect. Functional assays also showed increased TGF-β secretion and macrophage fusion when challenged with neutrophil extracellular traps (NETs). A small patient follow-up cohort treated with intra-articular PRP showed similar results, including normalization of cellular content and reduced CD64/CD206 expression. These findings indicate that PRP treatment effectively shifts SF-associated M1 macrophages to an M2-like phenotype, highlighting its potential as a therapeutic strategy for CHS.